Jing Ju1, Nan Wang2, Xinqun Wang3, Feihu Chen3. 1. College of Pharmacy, Anhui Medical University Hefei, Anhui 230032, China ; Department of Pharmacy, The Anqing Hospital Affiliated to Anhui Medical University Anqing, Anhui 246003, China. 2. Department of Pharmacy, The Anqing Hospital Affiliated to Anhui Medical University Anqing, Anhui 246003, China. 3. College of Pharmacy, Anhui Medical University Hefei, Anhui 230032, China.
Abstract
OBJECTIVE: This study is to investigate the in vivo effects of 4-amino-2-trifluoromethyl-phenyl retinate (ATPR) on gastric carcinomas (GC). METHODS: Adult male nude mice were subcutaneously injected with SGC-7901 human gastric cancer cells. Tumor cell cycle was analyzed with flow cytometry. The expression levels of cycloxygenase 2 (COX-2) and carcinoembryonic antigen (CEA) in xenograft tumors were detected with immunohistochemistry. The mRNA and protein expression levels of nuclear retinoic acid receptor β (RARβ) were detected with RT-PCR and Western blot analysis, respectively. RESULTS: The mean survival time was dramatically increased in the ATPR treatment groups, in a dose-dependent manner. The in vivo results showed that, the xenograft tumor growth was significantly inhibited by the ATPR treatment. Moreover, the percentages of cells in the G0/G1 phase were significantly increased, while the percentages of cells in the S phase were significantly decreased, in the ATPR treatment groups. The serum levels of ALP and LDH were both dramatically decreased in the ATPR treatment groups. Furthermore, immunohistochemistry showed that, the expression levels of COX-2 and CEA were dramatically decreased in the ATPR treatment groups. Importantly, the mRNA and protein expression levels of RARβ in xenograft tumors were apparently increased by the ATPR treatment. CONCLUSION: ATPR could inhibit proliferation and induce differentiation of human gastric carcinoma xenografts via up-regulating RARβ expression. ATPR might be a potential effective antitumor agent for the treatment of GC.
OBJECTIVE: This study is to investigate the in vivo effects of 4-amino-2-trifluoromethyl-phenyl retinate (ATPR) on gastric carcinomas (GC). METHODS: Adult male nude mice were subcutaneously injected with SGC-7901 humangastric cancer cells. Tumor cell cycle was analyzed with flow cytometry. The expression levels of cycloxygenase 2 (COX-2) and carcinoembryonic antigen (CEA) in xenograft tumors were detected with immunohistochemistry. The mRNA and protein expression levels of nuclear retinoic acid receptor β (RARβ) were detected with RT-PCR and Western blot analysis, respectively. RESULTS: The mean survival time was dramatically increased in the ATPR treatment groups, in a dose-dependent manner. The in vivo results showed that, the xenograft tumor growth was significantly inhibited by the ATPR treatment. Moreover, the percentages of cells in the G0/G1 phase were significantly increased, while the percentages of cells in the S phase were significantly decreased, in the ATPR treatment groups. The serum levels of ALP and LDH were both dramatically decreased in the ATPR treatment groups. Furthermore, immunohistochemistry showed that, the expression levels of COX-2 and CEA were dramatically decreased in the ATPR treatment groups. Importantly, the mRNA and protein expression levels of RARβ in xenograft tumors were apparently increased by the ATPR treatment. CONCLUSION:ATPR could inhibit proliferation and induce differentiation of humangastric carcinoma xenografts via up-regulating RARβ expression. ATPR might be a potential effective antitumor agent for the treatment of GC.
Authors: Xiao Yu Wu; Wen Tao Liu; Zhen Feng Wu; Che Chen; Jia Yun Liu; Guan Nan Wu; Xue Quan Yao; Fu Kun Liu; Gang Li Journal: Am J Cancer Res Date: 2016-09-01 Impact factor: 6.166
Authors: Song Wang; Jingtao Liu; Hao Wu; Anna Jiang; Kun Zhao; Kun Yan; Wei Wu; Haibo Han; Yanhua Zhang; Wei Yang Journal: Chin J Cancer Res Date: 2021-12-31 Impact factor: 5.087
Authors: M A Zaimy; A Jebali; B Bazrafshan; S Mehrtashfar; S Shabani; A Tavakoli; S H Hekmatimoghaddam; A Sarli; H Azizi; P Izadi; B Kazemi; A Shojaei; A Abdalaian; J Tavakkoly-Bazzaz Journal: Cancer Gene Ther Date: 2016-08-12 Impact factor: 5.987